EASL Studio Podcast S2 E10: LITMUS: Defining the colour of NAFLD

EASL Studio S2 E9: YI Choice: Propelling liver cell biology into the third dimension

EASL Studio podcast S2 E9: YI Choice: Propelling liver cell biology into the third dimension

EASL Studio S2 E8: Treatment of HBV-HDV coinfection in the era of entry inhibition

EASL Studio Podcast S2 E8: Treatment of HBV-HDV coinfection in the era of entry inhibition

EASL Studio S2 E7: JHEP Live on critical appraisal of classification, diagnosis and treatment of hepatic encephalopathy

EASL Studio Podcast S2 E7: JHEP Live on critical appraisal of classification, diagnosis and treatment of hepatic encephalopathy

EASL Studio S2 E6: Should anticoagulants be given to patients with cirrhosis to improve outcome?

EASL Studio Podcast S2 E6: Should anticoagulants be given to patients with cirrhosis to improve outcome?

EASL Studio S2 E5: New era for science dissemination: The role of social media

EASL Studio Podcast S2 E5: New era for science dissemination: The role of social media

EASL Studio S2 E4: Betablockers in cirrhosis: Has Baveno consensus gone too far?

EASL Studio Podcast S2 E4: Betablockers in cirrhosis: Has Baveno consensus gone too far?

EASL Studio S2 E3: Interview with Stephan Urban - From bench to bedside: Process of developing the first HBV/HDV entry inhibitor

EASL Studio Podcast S2E3: Interview with Stephan Urban - From bench to bedside: Process of developing the first HBV/HDV entry inhibitor

EASL Studio S2 E2: Fats or carbs, who is the real villain?

EASL Studio Special Edition: Live from Viral Hepatitis Elimination Conference 2022

EASL Studio S2 E1: New treatment options for hereditary cholestasis syndromes: A game-changer?

EASL Studio Podcast S2E1: New treatment options for hereditary cholestasis syndromes: A game-changer?

EASL Studio Special Edition: Highlights of Liver Cancer Summit 2022